Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study

被引：1

作者：

Kato, Junji ^{[1
]}

Namikawa, Kenjiro ^{[2
]}

Uehara, Jiro ^{[3
]}

Nomura, Motoo ^{[4
]}

Nakamura, Yasuhiro ^{[5
]}

Uhara, Hisashi ^{[1
]}

Uchi, Hiroshi ^{[6
]}

Yoshikawa, Shusuke ^{[7
]}

Kiniwa, Yukiko ^{[8
]}

Nakamura, Yoshiyuki ^{[9
]}

Miyagawa, Takuya ^{[10
]}

Matsushita, Shigeto ^{[11
]}

Takenouchi, Tatsuya ^{[12
]}

Hatta, Naohito ^{[13
]}

Ohno, Fumitaka ^{[14
]}

Maeda, Taku ^{[15
,16
]}

Fukushima, Satoshi ^{[17
]}

Yamazaki, Naoya

机构：

[1] Sapporo Med Univ, Dept Dermatol, Sapporo, Hokkaido, Japan

[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Dermatol Oncol, Tokyo, Japan

[4] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan

[5] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[6] Natl Hosp Org Kyushu Canc Ctr, Dept Dermatooncol, Fukuoka, Japan

[7] Shizuoka Canc Ctr, Div Dermatol, Shizuoka, Japan

[8] Shinshu Univ, Dept Dermatol, Nagano, Japan

[9] Univ Tsukuba, Dept Dermatol, Tsukuba, Ibaraki, Japan

[10] Univ Tokyo, Dept Dermatol, Grad Sch Med, Tokyo, Japan

[11] Natl Hosp Org Kagoshima Med Ctr, Dept Dermatooncol Dermatol, Kagoshima, Japan

[12] Niigata Canc Ctr, Dept Dermatol, Niigata, Japan

[13] Toyama Prefectural Cent Hosp, Dept Dermatol, Toyama, Japan

[14] Kyushu Univ, Dept Dermatol, Fukuoka, Japan

[15] Hokkaido Univ, Dept Plast & Reconstruct Surg, Fac Med, Sapporo, Hokkaido, Japan

[16] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan

[17] Kumamoto Univ, Dept Dermatol & Plast Surg, Kumamoto, Japan

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 187卷 / 04期

关键词：

DISCONTINUATION;

D O I：

10.1111/bjd.21276

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：594 / 596

页数：3

共 50 条

[1] Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study
Ochenduszko, Sebastian
Sanchez, Javier Garcia
Juan Fita, Maria Jose
Gonzalez-Barrallo, Ines
Herrero Colomina, Julio
Mujika, Karmele
Diaz Beveridge, Roberto
Ros Martinez, Silverio
Sanchez Lafuente, Blanca
Cunquero Tomas, Alberto
Berrocal Jaime, Alfonso
Cerezuela Fuentes, Pablo
Luna Fra, Pablo
Gervas Peeters, Alicia
Meana Garcia, Jose Andres
Algarra Garcia, Maria Asuncion
Perez Altozano, Javier
Cancela, Maria
Mateu Puchades, Almudena
Ferrando Roca, Francisco
Maestu Maiques, Inmaculada
PIGMENT CELL & MELANOMA RESEARCH, 2023, 36 (05) : 388 - 398
[2] Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience
Al jarroudi, Ouissam
Chaabouni, Hamed
Ulusakarya, Ayhan
Almohamad, Wathek
Gumus, Yusuf
Goldschmidt, Emma
Afqir, Said
Morere, Jean-francois
CLINICAL CASE REPORTS, 2021, 9 (04): : 2162 - 2167
[3] Adverse events associated with "Anti-programmed death-1" therapy for patients with melanoma
De Francesco, Adele Emanuela
De Fina, Mariarosanna
Zito, Maria Cristina
Bisceglia, Maria Dezia
Esposito, Stefania
Fersini, Giuseppina
JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
[4] Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.
Ochenduszko, Sebastian
Garcia, Javier
Juan-Fita, Maria Jose
Gonzalez-Barrallo, Ines
Colomina, Julio Herrero
Beveridge, Robert Diaz
Martinez, Silverio Ros
Lafuente, Blanca Sanchez
Tomas, Alberto Jacobo Cunquero
Berrocal, Alfonso
Cerezuela-Fuentes, Pablo
Fra, Pablo Luna
Peeters, Alicia Gervas
Gonzalez, Jose Luis Sanchez
Garcia, Andres Meana
Garcia, Mariasun Algarra
Garcia, Eugenio Palomares
Altozano, Javier Perez
Guerola, Monica Tallon
Maestu, Inmaculada
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma
Tang, Bixia
Mo, Jiazhi
Yan, Xieqiao
Duan, Rong
Chi, Zhihong
Cui, Chuanliang
Si, Lu
Kong, Yan
Mao, Lili
Li, Siming
Zhou, Li
Lian, Bin
Wang, Xuan
Bai, Xue
Xu, Huayan
Li, Caili
Dai, Jie
Guo, Jun
Sheng, Xinan
EUROPEAN JOURNAL OF CANCER, 2021, 156 : 83 - 92
[6] Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study
Xu, Ming-Hao
Huang, Cheng
Li, Mei-Ling
Zhu, Xiao-Dong
Tan, Chang-Jun
Zhou, Jian
Fan, Jia
Sun, Hui-Chuan
Shen, Ying-Hao
CANCER MEDICINE, 2023, 12 (08): : 9202 - 9212
[7] Durable response after cessation of anti-programmed death 1 therapy in four melanoma patients
Handa, Toshiya
Kato, Junji
Sumikawa, Yasuyuki
Hida, Tokimasa
Horimoto, Kohei
Sato, Sayuri
Sawada, Masahide
Fujioka, Mao
Minowa, Tomoyuki
Matsui, Yoshiyuki
Uhara, Hisashi
JOURNAL OF DERMATOLOGY, 2019, 46 (12): : e461 - e462
[8] Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients
Cybulska-Stopa, Bozena
Zietek, Marcin
Kaminska-Winciorek, Grazyna
Czarnecka, Anna M.
Piejko, Karolina
Galus, Lukasz
Ziolkowska, Barbara
Kieszko, Stanislaw
Kempa-Kaminska, Natasza
Calik, Jacek
Zemelka, Tomasz
Kubiatowski, Tomasz
Suwinski, Rafal
Mackiewicz, Jacek
Rutkowski, Piotr
MELANOMA RESEARCH, 2021, 31 (01) : 49 - 57
[9] A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer
Sun, Danyang
Ma, Junxun
Wang, Jinliang
Wang, Lijie
Zhang, Sujie
Chen, Guangying
Li, Xiaoyan
Cui, Pengfei
Zheng, Xuan
Hu, Yi
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 11 (06) : 1421 - +
[10] The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting
Kopecky, Jindrich
Pasek, Marek
Lakomy, Radek
Melichar, Bohuslav
Mrazova, Ivona
Kubecek, Ondrej
Arenbergerova, Monika
Lemstrova, Radmila
Svancarova, Alzbeta
Tretera, Vojtech
Hlodakova, Alzbeta
Zvackova, Kamila
CANCER MEDICINE, 2024, 13 (05):

← 1 2 3 4 5 →